10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting
PLEASANTON, Calif., June 7, 2022 /PRNewswire/ -- 10X Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced a series of product updates that will be presented at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Fla. The latest developments across 10x Genomics' leading Chromium and Visium platforms and the highly anticipated Xenium launch expected later this year showcase the company's leadership and innovation at the forefront of single-cell analysis, spatial biology, and in situ technology.
"With major advances in each of our three platforms, we are executing to make 2022 the most exciting year of product launches in our history," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics. "As the only company with technologies that cover single cell, spatial and in situ analysis, we're in the best position to fuel researchers' discoveries and unlock new biological insights that will ultimately advance human health. We look forward to demonstrating the power of 10x Genomics' leading platforms, showcasing researchers' success with our technologies and highlighting our robust product pipeline at AGBT."
In addition to the new developments announced today, 10x Genomics will host a workshop at AGBT on Thursday, June 9, at noon Eastern to share the latest data across its three platforms, including Xenium.
As part of the company's robust R&D pipeline, 10x Genomics is driving innovation to enable broad adoption of the Chromium single-cell platform by increasing access to more sample types, removing bottlenecks, and giving researchers a more flexible and streamlined workflow.
10x Genomics today announced the compatibility of its recently launched Fixed RNA Profiling Kit to enable single-cell transcriptomics on dissociated formalin-fixed, paraffin-embedded (FFPE) tissues. This groundbreaking capability enables single-cell analysis on preserved biobank samples for the first time ever. FFPE tissues are ideal for translational and clinical research, yet have remained inaccessible for single-cell analysis until now.
"Our Chromium platform has fueled thousands of discoveries and helped profile more than 5 billion cells, accelerating the scientific community's understanding and mastery of biology," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "Yet, all of these insights have been generated in prospective studies leveraging fresh or fresh-frozen tissues. Now, for the first time ever, researchers can look retrospectively and analyze FFPE tissues at single-cell resolution and scale. By opening up the archives for single-cell analysis, we have the potential to truly transform the future of health and medicine."
Both the Fixed RNA Profiling Kit and the previously announced Nuclei Isolation Kit, 10x Genomics' first sample preparation product, are now shipping.
10x Genomics announced the launch and pre-order availability of two new products in its Visium portfolio, the leading spatial discovery platform:
"Spatial genomics takes single-cell characterization to the next dimension, and 10x Genomics is leading the way in spatial biology with several new launches that will help further researchers' understanding of health and disease," said Schnall-Levin. "We are excited about the breadth of our spatial analysis product roadmap, which will help further the capabilities of the Visium platform with new technologies focused on enabling more analytes, more samples, and greater resolution."
Building on its leadership and innovation in single-cell and spatial analysis, 10x Genomics is planning to launch its Xenium platform for in situ analysis later this year.
"In situ analysis that allows for true single-cell spatial resolution is the next frontier of biology, and we're incredibly excited to launch our Xenium platform later this year," said Schnall-Levin. "The initial launch is just the beginning for us. We have an extensive, multi-year product roadmap that will unlock the full capabilities of the Xenium platform and deliver on the promise and potential of in situ analysis."
10x Genomics developed the Xenium platform by uniting its internal development with its 2020 acquisitions of CartaNa and ReadCoor, which provided intellectual property, key technology advances, and deep talent and expertise in the emerging in situ field. To date, the company has more than 200 patents issued and pending in the in situ field, including key patents for features related to high throughput and high sensitivity.
At launch, Xenium is expected to offer single-molecule RNA analysis at subcellular resolution and be compatible with both fresh frozen and FFPE tissues. In addition, 10x Genomics is developing Xenium to have the highest throughput of any instrument in its class.
10x Genomics expects to begin shipping the Xenium Analyzer by year-end.
10x Genomics will present five posters during AGBT demonstrating the use of its platforms to generate novel biological insights.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,700 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,350 issued patents and patent applications.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project" "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding our business operations, financial performance and results of operations, including our expectations regarding 10x Genomics, Inc.'s product roadmap, as well as our ability to meet our anticipated cash needs for the foreseeable future. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, as the COVID-19 pandemic is continuously evolving, such forward-looking statements may not accurately or fully reflect the potential impact that the COVID-19 pandemic may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-advances-leadership-and-innovation-in-single-cell-and-spatial-technologies-at-2022-agbt-general-meeting-301562442.html
SOURCE 10x Genomics, Inc.
Company Codes: NASDAQ-NMS:TXG